Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Cystorelin
2. Dirigestran
3. Factrel
4. Fsh Releasing Hormone
5. Fsh-releasing Hormone
6. Gn-rh
7. Gnrh
8. Gonadoliberin
9. Gonadorelin
10. Gonadorelin Acetate
11. Gonadorelin Hydrochloride
12. Gonadotropin Releasing Hormone
13. Gonadotropin-releasing Hormone
14. Kryptocur
15. Lfrh
16. Lh Fsh Releasing Hormone
17. Lh Releasing Hormone
18. Lh-fsh Releasing Hormone
19. Lh-releasing Hormone
20. Lh-rh
21. Lhfsh Releasing Hormone
22. Lhfshrh
23. Lhrh
24. Luliberin
25. Luteinizing Hormone Releasing Hormone
26. Luteinizing Hormone-releasing Hormone
27. Releasing Hormone, Lhfsh
1. Lhrh
2. Lh-rh
3. Gonadoliberin, Luliberin
4. Gnrh
5. 9034-40-6
6. 71447-49-9
7. Lhrh, Human
8. Ncgc00182043-01
9. 6918-09-8
10. Chembl1981292
11. Luteinizing Hormone Releasingfactor
12. Bcp12609
13. Bcp12654
14. Luteinizing Hormone Releasing Factor
15. Syntheticgonadotropin-releasinghormone
16. Db00644
17. Ncgc00389662-01
18. Luteinizing Hormone Releasing Hormone Human
19. Db-057197
20. Ft-0628048
21. C07607
22. A821811
23. L000690
24. Luteinizing Hormone Releasing Hormone Human Acetate Salt;lhrh
25. Lhrh;lh-releasing Factor;gonadorelina;glp-his-trp-ser-tyr-gly-leu-ser-pro-gly-nh2
26. N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-azanyl-2-oxidanylidene-ethyl)carbamoyl]pyrrolidin-1-yl]-5-[bis(azanyl)methylideneamino]-1-oxidanylidene-pentan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]amino]-3-(4-hydroxyphenyl)-1-o
27. N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[[(2-amino-2-oxoethyl)amino]-oxomethyl]-1-pyrrolidinyl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropa
Molecular Weight | 1182.3 g/mol |
---|---|
Molecular Formula | C55H75N17O13 |
XLogP3 | -2.4 |
Hydrogen Bond Donor Count | 16 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 31 |
Exact Mass | 1181.57302551 g/mol |
Monoisotopic Mass | 1181.57302551 g/mol |
Topological Polar Surface Area | 475 Ų |
Heavy Atom Count | 85 |
Formal Charge | 0 |
Complexity | 2390 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 8 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
Gonadorelin is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use
Absorption
Rapidly absorbed when injected
Rapidly hydrolyzed to inactive peptide components
Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes
Systemic - Like naturally occurring gonadotropin-releasing hormone (GnRH), gonadorelin primarily stimulates the synthesis and release of luteinizing hormone (LH) from the anterior pituitary gland. Follicle-stimulating hormone (FSH) production and release is also increased by gonadorelin, but to a lesser degree. In prepubertal females and some gonadal function disorders, the FSH response may be greater than the LH response. For the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A CHORIONIC GONADOTROPIN manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CHORIONIC GONADOTROPIN, including repackagers and relabelers. The FDA regulates CHORIONIC GONADOTROPIN manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CHORIONIC GONADOTROPIN API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CHORIONIC GONADOTROPIN manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CHORIONIC GONADOTROPIN supplier is an individual or a company that provides CHORIONIC GONADOTROPIN active pharmaceutical ingredient (API) or CHORIONIC GONADOTROPIN finished formulations upon request. The CHORIONIC GONADOTROPIN suppliers may include CHORIONIC GONADOTROPIN API manufacturers, exporters, distributors and traders.
click here to find a list of CHORIONIC GONADOTROPIN suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CHORIONIC GONADOTROPIN DMF (Drug Master File) is a document detailing the whole manufacturing process of CHORIONIC GONADOTROPIN active pharmaceutical ingredient (API) in detail. Different forms of CHORIONIC GONADOTROPIN DMFs exist exist since differing nations have different regulations, such as CHORIONIC GONADOTROPIN USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CHORIONIC GONADOTROPIN DMF submitted to regulatory agencies in the US is known as a USDMF. CHORIONIC GONADOTROPIN USDMF includes data on CHORIONIC GONADOTROPIN's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CHORIONIC GONADOTROPIN USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CHORIONIC GONADOTROPIN suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CHORIONIC GONADOTROPIN as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CHORIONIC GONADOTROPIN API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CHORIONIC GONADOTROPIN as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CHORIONIC GONADOTROPIN and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CHORIONIC GONADOTROPIN NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CHORIONIC GONADOTROPIN suppliers with NDC on PharmaCompass.
CHORIONIC GONADOTROPIN Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CHORIONIC GONADOTROPIN GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CHORIONIC GONADOTROPIN GMP manufacturer or CHORIONIC GONADOTROPIN GMP API supplier for your needs.
A CHORIONIC GONADOTROPIN CoA (Certificate of Analysis) is a formal document that attests to CHORIONIC GONADOTROPIN's compliance with CHORIONIC GONADOTROPIN specifications and serves as a tool for batch-level quality control.
CHORIONIC GONADOTROPIN CoA mostly includes findings from lab analyses of a specific batch. For each CHORIONIC GONADOTROPIN CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CHORIONIC GONADOTROPIN may be tested according to a variety of international standards, such as European Pharmacopoeia (CHORIONIC GONADOTROPIN EP), CHORIONIC GONADOTROPIN JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CHORIONIC GONADOTROPIN USP).
LOOKING FOR A SUPPLIER?